Physician Perspectives 2017: Use of Ustekinumab in IBD
Physician Perspectives newly adds in Orbisresearch.com database. This report covers leading key company profiles with information such as business overview, regional analysis, consumption, revenue and specification.
(EMAILWIRE.COM, October 23, 2018 ) This Physician Perspectives survey focuses on the use of ustekinumab in IBD.
UST appears to be the preferred non-TNF biologic for treatment of moderate-to-severe Crohn’s disease, most frequently prescribed after the failure of one or two anti-TNFs (most often IFX & ADA), and before VDZ.
73% of physicians reported having had high expectations of UST's efficacy, and 58% stated that these expectations had been met, while 12% stated that they had not been met.
Ask for PDF Sample with Full TOC at http://www.orbisresearch.com/contacts/request-sample/2350552
Majority of physicians expected UST to be somewhat effective or effective to treat UC patients with left-sided UC, non-acute, steroid dependent UC, extensive UC, ulcerative proctitis, acute severe colitis, and to treat patients with a high BMI.
The report includes following topics -
- Current clinical use of UST
- UST safety & efficacy
- UST patient monitoring
- Treatment response to UST
- UST treatment strategies
- Future use in UC.
Scope
- Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists
- Physicians interviewed were from 5EU and US countries
- This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.
Reasons to buy
- Qualitative insight from 100 high-prescribing specialists in IBD
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Companies Mentioned:
Janssen
Takeda
AbbVie
Else place an Inquire before Purchase@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2350552
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
UST appears to be the preferred non-TNF biologic for treatment of moderate-to-severe Crohn’s disease, most frequently prescribed after the failure of one or two anti-TNFs (most often IFX & ADA), and before VDZ.
73% of physicians reported having had high expectations of UST's efficacy, and 58% stated that these expectations had been met, while 12% stated that they had not been met.
Ask for PDF Sample with Full TOC at http://www.orbisresearch.com/contacts/request-sample/2350552
Majority of physicians expected UST to be somewhat effective or effective to treat UC patients with left-sided UC, non-acute, steroid dependent UC, extensive UC, ulcerative proctitis, acute severe colitis, and to treat patients with a high BMI.
The report includes following topics -
- Current clinical use of UST
- UST safety & efficacy
- UST patient monitoring
- Treatment response to UST
- UST treatment strategies
- Future use in UC.
Scope
- Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists
- Physicians interviewed were from 5EU and US countries
- This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.
Reasons to buy
- Qualitative insight from 100 high-prescribing specialists in IBD
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Companies Mentioned:
Janssen
Takeda
AbbVie
Else place an Inquire before Purchase@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2350552
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results